Antibody microarray-based oncoproteomics

Research output: Contribution to journalArticlepeer-review


The driving force behind oncoproteomics is the belief that certain protein signatures or patterns exist that are associated with a particular malignancy. if so, the correlation of clinical parameters with defined protein expression patterns would allow us to predict disease progression and perhaps even postulate improved therapeutic modalities. The technological challenges to achieve these goals are significant, as the human proteome is not defined. No general methodological approach exists today, and human cancer can, furthermore, be divided into several disease subgroups. One potential solution to finding cancer-associated protein signatures is the emerging technology of affinity proteomics. This approach addresses some of the shortcomings of traditional proteomics and combines it with the power of microarrays. The present review focuses on the role of antibody microarrays in oncoproteomics and its potential to provide a truly proteome-wide analytical approach.
Original languageEnglish
Pages (from-to)833-838
JournalExpert Opinion on Biological Therapy
Issue number8
Publication statusPublished - 2006

Subject classification (UKÄ)

  • Immunology in the medical area

Free keywords

  • recombinant
  • antibody
  • proteome analysis
  • microarray
  • affinity proteomics
  • cancer


Dive into the research topics of 'Antibody microarray-based oncoproteomics'. Together they form a unique fingerprint.

Cite this